Ann: Business Update, page-15

First 15 Last

Share
Profile

Follow
senderos

4,779 Posts.

384

01/02/18

22:10

Post #: 30753361
Share

Originally posted by waiken ↑

Hi Aqua
I see ANW and DHR being worth 0.50 each in the future. If you read carefully through all the anns for all the subs you will discover they hold world class resources.
I see SOLG as reaching well above Nick Mathers 60p option exercise price. 1 pound plus will be attained. SOLG currently possess a top 10 inferred cu/au resource of all time. Their huge holding along the Andean copper belt could result in them holding the largest cu/au resource of all the copper companies in the world if they retain all their properties. The initial MRE just for Alpala is spectacular. It alone would price any other coy above 50p. There is a very sophisticated game being played with the SOLG price. Buys then a sell or two at a reduced price. The manner of placing buys and sells on the LSE is fascinating. You can google it. It enables far more price manipulation than the ASX. The confidence of short term and medium holders in SOLG has been broken. This is evidenced by the capitulatory selling and the volume of negative uncertain and frustrated posts on the SOLG forum. For someone who studied psychology before accounting this is a fascinating study for me in the manipulation of human sentiment. At 0.20p I see SOLG as a 5 bagger. A takeover is the end game as DGR and the directors of SOLG don't control enough shares to prevent it. A bid of 1 pound at present would take out all the private holders and most of the instos. I see DGR as an AUD 1.00-2.00 plus stock. It will not be taken over at a sub optimal price like SOLG as directors, staff and loyalists like Tenstar control around 50% of the shares. Also directors and staff will retain their remuneration and option flow as long as possible. DGR is the best bet in the group as it will never go at a discount. It is the mother ship and completely controlled.

Expand

SOLG just did a 15 % turn from 20.5 p. It has been manipulated. Wait till DRILL bits hit Aquinaga. Back into the waiting room.

DGR Price at posting: 9.3¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

There are more pages in this discussion • 8 more messages in this thread...

First 15 Last

Add DGR (ASX) to my watchlist

(20min delay)
Last 1.5¢		Change 0.002(15.4%)		Mkt cap ! $15.65M

Open	High	Low	Value	Volume
1.5¢	1.5¢	1.5¢	$3K	199.9K

Buyers (Bids)

No.	Vol.	Price($)
1	600000	1.5¢

Sellers (Offers)

Price($)	Vol.	No.
1.6¢	540000	1

View Market Depth

No.	Vol.	Price($)
1	600000	0.015
1	36428	0.014
6	1203325	0.013
2	443333	0.012
1	181818	0.011

Price($)	Vol.	No.
0.016	540000	1
0.018	1027000	2
0.019	613240	1
0.020	1532270	2
0.025	32000	1

Last trade - 10.55am 07/10/2024 (20 minute delay)

DGR (ASX) Chart

Ann: Business Update, page-15

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Business Update, page-15

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News